What Is Humanin?
Humanin is a small peptide first identified during a search for genes that protected nerve-like cells from Alzheimer-related stress. It is described as a mitochondrial-derived peptide because an open reading frame within the mitochondrial 16S ribosomal RNA gene can encode it.
Humanin has been studied extensively in cells and animals for effects on cell death, metabolism, inflammation and stress resistance. Researchers have also measured humanin-like immunoreactivity in human blood and tissues. Those observations do not amount to trials showing that administered humanin treats Alzheimer’s disease, diabetes, cardiovascular disease or ageing.
Identity requires care. Depending on where translation occurs and which genetic code is applied, papers discuss a 21-amino-acid mitochondrial sequence or a 24-amino-acid cytoplasmic form. More potent laboratory analogues, especially HNG or S14G-humanin, are different molecules.
Where does humanin come from?
The mitochondrial genome contains 37 familiar genes, mostly for respiratory-chain proteins, transfer RNAs and ribosomal RNAs. Researchers discovered that small open reading frames within regions annotated for other functions can also encode micropeptides.
Humanin’s open reading frame lies within MT-RNR2, the gene for mitochondrial 16S ribosomal RNA. Related sequences copied into the nuclear genome are called nuclear mitochondrial DNA segments, and some humanin-like genes may also be expressed.
The mitochondrial genetic code differs from the nuclear code. Translation inside mitochondria predicts a 21-residue peptide because one codon acts as a stop. Cytoplasmic translation can produce a 24-residue form. Assays do not always distinguish these forms or related humanin-like peptides.
Why is humanin’s genetic identity unusually complicated?
Most familiar mitochondrial proteins are encoded by clearly annotated genes and translated through established mitochondrial machinery. Humanin instead comes from a short open reading frame embedded within a region already assigned another function: the MT-RNR2 ribosomal RNA gene.
Copies of mitochondrial sequence have also accumulated in the nuclear genome over evolution. These nuclear mitochondrial DNA segments can resemble the humanin open reading frame, and several are described as humanin-like genes. Detecting a related RNA sequence therefore does not by itself prove which genomic copy produced a peptide.
Translation location matters as well. The mitochondrial and universal genetic codes interpret some codons differently, producing the proposed 21- and 24-residue versions. Research papers and commercial catalogues sometimes say “humanin” without specifying which sequence, whether terminal modifications are present or whether an analogue was used.
For evidence appraisal, the exact peptide sequence is part of the intervention—not a minor naming detail.
How was humanin discovered?
In 2001, investigators screened complementary DNA from a relatively preserved brain region of a person with familial Alzheimer’s disease. They looked for sequences that protected cells against toxic Alzheimer-related genes and identified humanin.
Subsequent work reported that humanin could suppress cell-death pathways triggered by amyloid-related or other stresses. A 2003 study found direct interaction with Bax, a protein that promotes mitochondrial outer-membrane permeabilisation during apoptosis.
| Period | Development |
|---|---|
| 2001 | Humanin identified in a functional survival screen |
| 2003 onward | Intracellular apoptosis interactions and extracellular signalling investigated |
| 2010s | Humanin placed within a broader mitochondrial-derived peptide field |
| 2020s | Human cohort associations and animal disease models expanded |
| Current position | No approved humanin medicine and no established administered-human efficacy programme |
The discovery method explains both the interest and the limitation. Humanin was selected because it rescued cultured cells under specific experimental stress. It was not discovered through a clinical trial or because a human deficiency syndrome improved when the peptide was replaced.
The name reflects the original investigators’ hope that the factor might recover “humanity” from disease. It does not mean the peptide has been demonstrated to treat people.
How might humanin signal?
Inside cells, humanin has been reported to bind proteins involved in apoptosis, including Bax, and to interfere with steps leading to mitochondrial membrane permeabilisation. Apoptosis is an organised cell-death programme used in development and tissue maintenance.
Outside cells, studies propose receptor systems involving formyl-peptide receptor-like proteins or a complex containing CNTFR, WSX-1 and gp130. Downstream signals can include JAK/STAT, ERK and PI3K-Akt pathways. These are broad networks involved in survival, inflammation and metabolism.
Different sequences, cell types and concentrations can produce different findings. A protective effect in a stressed cell culture does not prove benefit in a person, because controlled cell removal can also be protective for the organism.
Intracellular and extracellular actions are not the same
Intracellular humanin has been studied as a binding partner for pro-apoptotic BCL-2-family proteins. Bax and related proteins help form pores in the mitochondrial outer membrane, releasing factors that commit a cell to apoptosis. Experimental humanin can interfere with Bax activation, membrane association or oligomerisation.
Secreted humanin is proposed to act through cell-surface receptors. Reported systems include formyl-peptide receptor 2 and a tripartite complex containing CNTFR, WSX-1 and gp130. These routes can activate survival and metabolic signalling networks such as STAT3, ERK and PI3K-Akt.
The distinction affects translation. A peptide added outside a cell may not reproduce local production inside a particular organelle. Conversely, raising a circulating peptide could expose tissues that were not involved in the original cell experiment. Mechanism papers should therefore be matched to the form, location and exposure actually tested.
What is HNG or S14G-humanin?
HNG is a synthetic analogue in which serine at position 14 is replaced by glycine. It is often described as much more potent in selected laboratory assays.
That substitution creates a separate molecule. Evidence from HNG must not be attributed automatically to native humanin. Other analogues alter residues to emphasise neuroprotection, receptor signalling or metabolic effects.
Commercial “humanin” labels may fail to state whether the product is 21 residues, 24 residues, HNG or another analogue. Without a sequence, the name is incomplete.
| Name used in research | Defining feature | Why evidence cannot be merged automatically |
|---|---|---|
| Native humanin | Commonly described as a 24-residue peptide | Sequence and translation context must be stated |
| Mitochondrial-code form | Proposed 21-residue sequence | Different length and potentially different handling |
| HNG or S14G-humanin | Glycine replaces serine at position 14 | Engineered analogue with greater potency in selected assays |
| Other derivatives | Additional substitutions or terminal changes | Receptor activity, stability and distribution may differ |
What does the cell evidence show?
Cell studies report protection against amyloid-beta toxicity, oxidative stress, serum withdrawal and some drug-induced injuries. Researchers have examined neurons, pancreatic beta cells, vascular cells and germ cells.
Cell culture is valuable for mechanism, but exposure can be far above physiological levels and cells lack whole-body metabolism, immunity and distribution. Reduced cell death may be beneficial in degenerative injury but harmful if it lets a damaged or malignant cell persist.
What do animal studies show?
Humanin and its analogues have been studied in rodents for cognitive impairment, stroke-like injury, diabetes, insulin resistance, atherosclerosis and age-related decline. Some experiments report improved memory tasks, glucose handling, endothelial function or tissue survival.
These models are not interchangeable. A transgenic Alzheimer model does not reproduce the full human disease, and an acute toxin injury is not normal ageing. Many studies use HNG rather than native humanin.
Administration route, formulation and timing often begin before or near an induced injury, whereas patients may have established disease for years. Positive animal results support further research, not a treatment claim.
Why do Alzheimer-model results not establish an Alzheimer treatment?
Many experiments expose cultured neurons to amyloid-related stress or use rodents with selected Alzheimer-associated genes. These systems isolate mechanisms and can show whether a peptide changes a particular toxic pathway.
Human Alzheimer’s disease develops over years and involves amyloid, tau, inflammation, vascular factors, synaptic loss and substantial biological heterogeneity. A short-term improvement in a rodent memory task does not demonstrate slowed clinical decline, preserved independence or acceptable long-term safety in people.
The earliest humanin experiments also used familial Alzheimer-related constructs. Most people with Alzheimer’s disease do not carry those rare familial variants. Extrapolation from a cellular rescue screen to routine dementia treatment therefore requires several evidentiary steps that have not occurred.
What human evidence exists?
Human evidence is mainly observational. Studies have measured circulating humanin-like levels and reported associations with age, insulin sensitivity, cardiovascular disease, Alzheimer’s disease, MELAS and exceptional longevity.
An association does not show direction or causation. Lower humanin could contribute to disease, result from disease, reflect kidney clearance or simply travel with another factor. Immunoassays may cross-react with related peptides and do not always identify exact sequence.
No robust randomised trial was identified in which a defined humanin peptide was administered to test clinical benefit. Claims that it treats dementia, diabetes or ageing therefore go beyond the evidence.
What do registered human studies actually investigate?
Registered humanin studies identified in trial databases are primarily observational. For example, one study measures humanin isoforms in cardiac muscle and plasma and asks whether levels associate with complications after cardiac surgery. Other protocols examine circulating levels in kidney injury or chronic disease.
These studies may evaluate humanin as a biomarker. They do not administer a therapeutic product, test a clinical dose or demonstrate that changing the measured level improves an outcome.
Why are blood-level studies difficult to compare?
Humanin concentrations are often measured with antibody-based assays. Antibodies can cross-react with related humanin-like peptides or fragments, and different assay kits may have different calibration and detection limits. Sample type, processing time, kidney function and storage can also influence results.
Consequently, an association reported in one cohort may not define a universal “optimal” concentration. Findings have not always pointed in the same direction: high levels can be interpreted as a protective longevity signal in one setting and as a response to mitochondrial stress or disease burden in another.
How would synthetic humanin be manufactured?
A 21- or 24-amino-acid humanin peptide can be made using solid-phase peptide synthesis. The manufacturer must define the exact sequence, terminal chemistry and salt form. HNG requires the specified glycine substitution.
After assembly and cleavage from the resin, chromatography can remove many truncated and modified chains. Mass spectrometry confirms molecular mass, while sequence-sensitive analysis helps distinguish closely related forms. Content, counterions, residual solvents, oxidation and aggregation also require testing.
Material intended for injection would need validated sterility, bacterial-endotoxin, particle and stability controls. A research certificate reporting chromatographic purity does not demonstrate suitability for human administration.
What evidence would be needed before therapeutic use could be assessed?
A development programme would first need one exact molecular candidate and a reproducible pharmaceutical formulation. Nonclinical work would need to define distribution, breakdown products, receptor activity, immune effects, reproductive toxicity, tumour-related risk and exposure margins.
Early human research would then need to establish pharmacokinetics and safety before testing efficacy in one clearly defined condition. Biomarkers could help show target engagement, but clinical outcomes would still be necessary. An Alzheimer programme, for example, would require validated cognitive and functional measures over sufficient time—not only a change in circulating humanin.
None of those steps can be replaced by combining unrelated positive cell and animal experiments. The broad range of proposed uses is a reason for sharper disease-specific development, not for assuming universal cytoprotection.
Could humanin support tumour cells?
Humanin is often presented as universally protective, but cell survival is context dependent. Experimental work has reported that humanin can support tumour progression or resistance in some models. Other studies explore anti-tumour contexts.
This does not establish that humanin causes cancer in people. It shows why a broadly cytoprotective signal needs tumour-specific and long-term safety testing. Protecting stressed normal cells and protecting abnormal cells can involve overlapping pathways.
The cancer evidence also varies by model. In experimental triple-negative breast cancer, systemic humanin reduced tumour-cell apoptosis, impaired chemotherapy effects and accelerated tumour growth and metastasis. Separate models have reported different interactions. This is a safety signal requiring clarification, not proof of a uniform human cancer effect.
Is humanin approved or prohibited in sport?
Humanin is not an FDA-, EMA- or UK-approved medicine. There is no authorised anti-ageing or neuroprotective humanin injection.
Athletes should check the current WADA list and obtain expert anti-doping advice. A substance need not be named individually if it falls within a broader prohibited category, and contaminated research products create additional risk.
What claims are not established?
Administered humanin has not been shown in controlled human trials to prevent ageing, improve cognition, treat Alzheimer’s disease, reverse diabetes, protect the heart, increase exercise performance or extend lifespan.
Natural blood-level associations do not supply a therapeutic target, dose or desired concentration. Animal use levels are not human recommendations.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Is humanin a biologically active peptide? | Cell, biochemical and animal studies | Yes, activity is well supported in experimental systems |
| Is endogenous humanin measurable in people? | Tissue and circulating immunoreactivity studies | Humanin-like signals are measurable, but assay and isoform limitations matter |
| Does administered humanin treat Alzheimer’s disease or diabetes? | No robust randomized therapeutic trial identified | No clinical efficacy conclusion can be made |
| Does humanin slow human ageing or extend lifespan? | Observational associations and animal experiments | Not established |
| Is chronic administration safe? | No adequate administered-human safety programme | Unknown, with tumour biology among the unresolved concerns |
This evidence base supports a detailed research guide, but it has a firm ceiling. Humanin remains a discovery and translational topic rather than a clinically validated therapy.
Frequently asked questions
Is humanin made by mitochondria?
Its coding sequence lies within mitochondrial MT-RNR2, although nuclear copies and the site of translation complicate the answer.
How long is humanin?
Papers discuss 21- and 24-amino-acid forms depending on translation context.
What is HNG?
It is the S14G humanin analogue, a different and often more potent laboratory molecule.
Is humanin a hormone?
It can signal within and between cells, but its physiology is not as completely established as classical hormones.
Does humanin prevent apoptosis?
It can reduce selected experimental cell-death pathways. That is not always beneficial in every tissue.
Has it been administered in clinical trials?
No robust therapeutic efficacy trial of a defined humanin product was identified.
Does it treat Alzheimer’s disease?
No controlled human evidence establishes treatment benefit.
Does it improve insulin sensitivity?
Animal and association studies are interesting, but administered-human efficacy is unproven.
Does humanin extend lifespan?
No human trial shows lifespan extension.
Could it affect cancer?
Pro-survival signalling has promoted tumour progression in some experimental models, making this an unresolved safety area.
Is humanin approved?
No.
Are online products reliably identified?
Not from the name alone. Exact sequence, analogue, amount, purity and sterility require verification.
Are animal amounts recommendations?
No. They describe experiments only.
Sources
Research reviewed through September 2026.